Urate-lowering therapy

Intervention1 paper2 findings

Humans1

Associations

2

Mortality

upin humans1HR 1.52Low certainty

1 study

Urate-lowering therapy raises the risk of mortality in humans (HR 1.52, 95% CI 1.27-1.82).
Humansmedian follow-up of 3.03 years
Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study · Frontiers in endocrinology · 31 Aug 2026

Composite cardiometabolic outcome

upin humans1HR 1.18Low certainty

1 study

Urate-lowering therapy raises the risk of composite cardiometabolic outcome in humans (HR 1.18, 95% CI 1.07-1.30).
Humansmedian follow-up of 3.03 years
Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study · Frontiers in endocrinology · 31 Aug 2026

Composite cardiometabolic outcome →

Latest

1

Frontiers in EndocrinologyHumans15 Sep

Early urate-lowering therapy and cardiometabolic risk in adults without documented major cardiometabolic disease: a real-world cohort study